Lisata Therapeutics (NASDAQ:LSTA) Posts Quarterly Earnings Results, Beats Expectations By $0.41 EPS

Lisata Therapeutics (NASDAQ:LSTA) announced its earnings results on Thursday. The company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.74) by $0.41, FiscalAI reports. The firm had revenue of $0.10 million during the quarter.

Lisata Therapeutics Stock Performance

LSTA remained flat at $5.03 on Thursday. 58,516 shares of the company were exchanged, compared to its average volume of 207,094. Lisata Therapeutics has a one year low of $1.81 and a one year high of $5.07. The firm has a 50 day moving average price of $3.80 and a two-hundred day moving average price of $2.79. The firm has a market capitalization of $44.36 million, a P/E ratio of -2.36 and a beta of 1.28.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on LSTA shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Lisata Therapeutics in a research report on Thursday, January 22nd. Brookline Capital Acquisition cut Lisata Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, January 21st. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $23.50.

Hedge Funds Weigh In On Lisata Therapeutics

A number of institutional investors have recently modified their holdings of the stock. Cerity Partners LLC bought a new stake in shares of Lisata Therapeutics during the second quarter valued at approximately $32,000. CIBC Bancorp USA Inc. purchased a new position in Lisata Therapeutics during the 3rd quarter worth $37,000. Finally, Renaissance Technologies LLC raised its position in Lisata Therapeutics by 6.1% during the 4th quarter. Renaissance Technologies LLC now owns 123,715 shares of the company’s stock valued at $230,000 after purchasing an additional 7,093 shares in the last quarter. 8.94% of the stock is owned by hedge funds and other institutional investors.

About Lisata Therapeutics

Lisata Therapeutics, Inc (NASDAQ: LSTA) is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for severe diseases. The company’s pipeline comprises multiple product candidates in both preclinical and clinical stages, targeting autoimmune and inflammatory conditions through immunotherapeutic and cell-based approaches.

Lisata’s research and development activities are designed to improve upon existing treatment modalities by emphasizing targeted biologics and precision cell therapies.